
GOSS Stock Forecast & Price Target
GOSS Analyst Ratings
Bulls say
Gossamer Bio is poised for success with their innovative product pipeline and strong partnerships as seen by their successful PROSERA data and positive outlook from key opinion leaders. Additionally, the company's cost-cutting measures and positive cash flow projections demonstrate their ability to navigate the competitive biopharmaceutical industry and meet their goal of NDA submission by September 2026. The recent dip in stock price provides an attractive entry point for potential investors looking to capitalize on the company's potential growth.
Bears say
Gossamer Bio is facing potential financial challenges due to its cash runway only extending until 2027. Additionally, there are uncertainties surrounding the regulatory path for its drug seralutinib, as well as doubts about the drug's market opportunity. With a new price target of $1 per share and a Neutral rating, there must be additional regulatory clarity for the company's outlook to improve.
This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GOSS Analyst Forecast & Price Prediction
Start investing in GOSS
Order type
Buy in
Order amount
Est. shares
0 shares